5
Participants
Start Date
August 11, 2020
Primary Completion Date
April 1, 2021
Study Completion Date
April 1, 2021
RVT-1401 680 mg/weekly
Non-randomized subjects will receive subcutaneous injection of 680 mg weekly for 12 weeks of RVT-1401
RVT-1401 340 mg/weekly
Non-randomized subjects will receive subcutaneous injection of 340 mg weekly for 12 weeks of RVT-1401
Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Bangkok
Seoul National University Bundang Hospital, Seongnam
Gachon University Gil Medical Center, Incheon
Leo W. Jenkins Cancer Center, Greenville
Hospital Universitario Quirón, Madrid
Faculty of Medicine, Khon Kaen University, Srinagarind Hospital, Khon Kaen
Norton Cancer Institute, Louisville
University of Michigan - Internal Medicine Division of Hematology/Oncology, Ann Arbor
Faculty of Medicine, Chiang Mai University, Maharaj Nakorn Chiang Mai Hospital, Chiang Mai
University of Iowa Hospitals & Clinics, Iowa City
Faculty of Medicine, Prince of Songkla University,Songklanagarind Hospital, Hat Yai
Ha'Emek Medical Center, Afula
Carmal MC, Haifa
Meir Medical Center, Kfar Saba
Massachusetts General Hospital Cancer Center - Hematology/Oncology, Boston
Korea University Anam Hospital, Seoul
Seoul National University Hospital - Department of Internal Medicine, Seoul
Asan Medical Center, Seoul
Samsung Medical Center, Seoul
Hospital Universitario Quirónsalud Madrid, Barcelona
Royal Cornwall Hospital, Truro
Lead Sponsor
Immunovant Sciences GmbH
INDUSTRY